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Cervical carcinoma is the second most common type of cancer in
females worldwide, with over 500 000 new cases diagnosed each
year. However, the incidence is declining in developed countries
owing to established cytological screening programmes. 
In most cancer registries, close to 75% of the tumours are reported
to be of the squamous type. Adeno- and adenosquamous carcinomas
represent about 10–15% and invasive tumours with unspecified
histology constitute the remaining 10–15% (Paloma et al, 1998). 
It is now widely accepted that the human papillomavirus (HPV)
is the major causal factor in most, if not all cervical cancers. This
fact makes cervical cancer probably the most common virally
caused cancer (Zur Hausen, 1991). 
However, the prevalence of HPV in squamous carcinoma is
almost 100% (Walboomers et al, 1999), but in cervical adenocarci-
noma, it is only about 70%, according to recent reports (Iwasowa
et al, 1996; Paloma Vizcaino et al, 1998). 
HPV 16 is the most commonly detected genotype in pre-invasive
and invasive squamous carcinoma (50–60%), followed by HPV 18
which is present in about 15% of the tumours (Zehbe and
Wilander, 1997a). However, in cervical adenocarinoma, HPV 18 is
the predominating type of virus followed by HPV 16 (Tenti et al,
1996). 
Molecular biological studies have revealed that a polymorphism
at codon 72 of the human tumour-suppressor gene, p53, results in
translation to either arginine or proline. The risk of the development
of cervical cancer associated with the human papillomavirus is
considered higher for women homozygous for arginine than for
those who are heterozygous. (Storey et al, 1998). However, this
observation is both confirmed and contradicted by several groups
(Hildesheim-A et al, 1998; Josefsson et al, 1998; Rosenthal et al,
1998; Zehbe et al, 1999; Agorastos et al, 2000; Makni et al, 2000).
The aim of the present investigation was to examine polymor-
phism in p53, codon 72, in women with invasive cervical adeno-
carcinomas and to compare the results with those of previous
studies performed on patients with pre-invasive and invasive
cervical squamous carcinomas. Furthermore, we intended to
examine whether the p53 polymorphism was correlated with an
HPV infection in the tumours. 
MATERIAL AND METHODS 
Tumour material 
A collection of cervical adenocarcinomas was used for the study.
Tumour blocks were obtained from different Departments of
Pathology, with the aid of the Cancer Registry of the National
Board of Health and Welfare in Sweden. The material has previ-
ously been described in detail (Andersson et al, 2001). 
The original collection consisted of formalin-fixed (tumour
blocks) from 180 women which were sectioned and stained with
haematoxylin-eosin for light microscopic analysis. From the light
microscopic examination and the women’s medical records, 23
tumours were considered to be of non-cervical origin, 14 tumours
were classified as squamous carcinomas and 9 as adenosquamous
carcinomas. 131 relevant cases, selected after microscopic
analysis and evaluation of the medical records of the women, were
further used. However, due to a lack of sufficient material for
DNA extraction or a negative β -globin test (see below) an additional
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HPV tests and the examination of p53, codon 72, polymorphism. 
DNA extraction 
DNA was isolated in one 10-µ m thick section from each selected
tissue block (Lungu et al, 1992). The sections were treated for 3
hours with 500 µ gm l –1 proteinase K in 150 µ l digestion buffer (50
mM KCl, 10 mM Tris-HCl, pH 8.3) at 65˚C. The enzyme was then
inactivated by boiling for 10 min. 
HPV-testing 
The HPV tests were performed as described earlier (Zehbe et al,
1996; Zehbe and Wilander, 1997). Briefly, the analyses were
performed on extracted DNA (Lungu et al, 1992) obtained from
sections of the paraffin blocks of which the preceding section had
been used for morphological diagnosis. In the first sequence, the
availability of tissue DNA was examined by performing a β -
globin test (Saiki et al, 1988). Secondly, the extracted DNA was
analysed with the SHARP Signal System (Digene Diagnostics,
Beltsville, MD) (Manos et al, 1989; Zehbe and Wilander, 1997)
using MY09/MY11 primers from the L1 gene of HPV. 
Specimens showing HPV of a high-risk type were subjected to
HPV typing (HPV of a low-risk type was not observed in our
material). HPV DNA from the L1 region was amplified with
GP5+/GP6+ primers and the amplicon products were HPV-typed
by single-strand conformational polymorphism (SSCP). The
method has previously been described in detail (De Roda Husman
et al, 1995; Zehbe et al, 1996). 
To optimise the HPV PCR analysis, all HPV-negative adenocar-
cinomas were subjected to a second HPV test using specific
primers from the E6 genes of HPV 16 and 18 for the PCR reaction
(Alemi et al, 1999) (Table 1). Thereafter, PCR products, indicating
infection with HPV 16 or 18, were identified on agarose gels. 
p53 polymorphism test 
The  p53 exon 4 PCR reaction was performed with two 21 bp
primers (Table 1), and at an annealing temperature of 62˚C
resulting in a 155-bp reaction product. 
For p53 genotyping, single-strand conformation polymorphism
(SSCP) was used, employing the Gene Gel Excel 12.5 kit
(Pharmacia Biotech, Uppsala, Sweden). The PCR products were
run on a GenePhor Electrophoresis Unit at 400 V, 25 mA, 12˚C for
100 min. After separation, the 12.5% polyacrylamide gel was
silver-stained in a Hoefer Automated Gel Stainer together with the
Plus One DNA Silver Staining kit (Figure 1). 
DNA preparations obtained from cytobrush specimens in the
188 normal females (25–60 years old), participating in the organ-
ised gynaecological screening in the county of Uppsala, were used
as controls in the p53, codon 72 genotype study. 
Statistical analysis 
The χ 2 test for trend was used for the statistical comparison of the
proportions (Breslow and Day, 1980). 
RESULTS 
Of the 131 adenocarcinomas collected for the study, a successful
β -globin test and a p53, codon 72 analysis were obtained in 111
tumours. They were of the papillary or glandular type and lacked a
squamous component. 
HPV analysis 
By using the MY09/MY11 primers from the HPV L1 gene for the
PCR reaction and the SHARP Signal System, 77/111 (69%) of the
tumours were determined HPV positive. With the application of
the specific HPV 16 E6 and HPV 18 E6 primers on the remaining
HPV negative tumours, an additional 9 cases 86/111 (77%)
showed HPV DNA, of which HPV 16 was identified in 4, and
HPV 18 in 5 tumours, respectively. In the HPV positive adenocar-
cinomas, 48/86 (43%) were infected with HPV 18, 31/86 (31%)
with HPV 16 and the remaining 7/86 (7%) with other or unknown
types of HPV. 25 (23%) cases were HPV negative (Table 2). 
p53 analysis 
The 3 p53, codon 72, genotypes arg/arg, arg/pro and pro/pro all
gave divergent band patterns with the PCR-SSCP analysis as illus-
trated in Figure 1. 
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Table 1 Primers used for PCR 
Primer Sequence 5′ –3′ Position Length  (bp) Product 
pair of gene size (bp) 
β -globin/PCO4 CAACTTCATCCACGTTCACC 54–73 20 268 
β -globin/GH20 GAAGAGCCAAGGACAGGTAC 195–176 20 
HPV/MY09 CGTCCMARRGGAWACTGATCa L1 (HPV6) 20 398 
HPV/MY11b GCMCAGGGWCATAAYAATGGa 20 
HPV/GP5+ TTTGTTACTGTGGTAGATACTAC L1 (HPV16) 23 141 
HPV/GP6+ GAAAAATAAACTGTAAATCATATTC L1 (HPV16) 25 
HPV 16 CTAAAATTAGTGAGTATAGACATTA E6 25 176 
HPV 16 CCTTATATTATGGAATCTTTGC E6 22 
HPV 18 ATGTTGCCTTAGGTCCATGCA E6 21 570 
HPV 18 ACCGAAAACGGTCGGGACC E6 19 
p53, codon 72 GACCCAGGTCCAGATGAAGCT Exon 4 21 155 
p53, codon 72 ACCGTAGCTGCCCTGGTAGGT Exon 4 21 
HPV, Human papillomavirus. 
aDegenerate code, M = A + C; R = A + G; W = A + T; X = G + C. 
bBiotinylated at its 5′ end. In the 188 normal female controls, the distribution of genotypes
was arg/arg 47%, arg/pro 44% and pro/pro 9%. The corresponding
figures for the cervical adenocarcinomas were arg/arg 71%,
arg/pro 29% and pro/pro 0%. The difference between normal
controls and women with cervical adenocarcinomas was statisti-
cally highly significant (P < 0.001). However, the small difference
obtained between HPV-positive and HPV-negative tumours was
not statistically significant (P = 0.690) (Table 3). 
DISCUSSION 
The prevalence of HPV observed and the distribution of the
different types of HPV that we identified in the cervical adenocar-
cinomas are in general agreement with previous observations of
these tumours (Iwasawa et al, 1996; Paloma Vizcaino et al, 1998).
These findings emphasise the existence of some pathogenetic
difference in comparison to the cervical squamous carcinomas,
which are almost always HPV positive and where HPV 16
predominates over HPV 18. Recently, it was shown that women
with HPV positive adenocarcinomas are younger than those with
HPV negative adenocarcinomas (Tenti et al, 1996; Andersson 
et al, 2001). Moreover, this observation indicates that carcinogenic
factors other than HPV are involved in the development of at least
some cervical adenocarcinomas. 
Since the original report by Storey et al (Storey et al, 1998) that
women with the p53 codon 72 arg/arg genotype are at an increased
risk of developing cervical carcinomas, a series of publications has
occurred dealing with this enigma. The results of several investi-
gations are concordant with those of Storey et al (Storey et al,
1998; Zehbe et al, 1999), whereas several others are unable to
support the finding (Minaguchi et al, 1998; Klaes et al, 1999;
Brooks et al, 2000). All these studies are performed on squamous
carcinomas or tumours without defined histological typing. 
In the present report of pure cervical adenocarcinomas, we
found a significant increase (P = 0.001), of the arg/arg in compar-
ison with normal controls. Thus, in Swedish women, adenocarci-
nomas and squamous carcinomas of the cervix seem to manifest
identical behaviour, since in a previous investigation in Sweden,
women with the arg/arg genotype were correlated to an increased
risk of developing squamous carcinoma (Zehbe et al, 1999). The
distribution of p53 codon 72 genotypes, which we found in the
normal female population, is equivalent to that observed in a
previous study of Swedish women (Zehbe et al, 1999). However,
the prevalence of the different p53, codon 72, genotypes is
unequally distributed in several countries and therefore the impor-
tance of the arg/arg genotype in the development of cervical cancer
is of variable significance (Tenti et al, 1998). Furthermore, since
the p53 polymorphism was not distributed differently among HPV-
positive and -negative adenocarcinomas, it is suggested that the
increased risk of cervical adenocarcinoma in arg/arg women is not
directly related to the HPV infection. Our results further support
the opinion that polymorphism in the human genoma, at a critical
site, can affect the rate of incidence of cancer (Rosenthal et al,
1998; Storey et al, 1998). In addition, single-point mutations in the
DNA of oncogenic types of HPV can have a corresponding biolog-
ical potential. For instance, an amino acid shift in codon 83 of the E6
protein of HPV 16 Leu<Val seems to increase both the persistence
p53 polymorphism in cervical adenocarcinomas 1155
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Figure 1 PCR-SSCP genotyping of the p53 codon 72 polymorphism. The
lanes show women homozygotic for pro/pro (lane 1), heterozygotic for
arg/pro (lane 3) and homozygotic for arg/arg (lane 2), respectively 
Table 2 Prevalence of various genital types of HPV identified in the cervical
adenocarcinomas 
Cervical Number 
adenocarinomas of cases (%)
HPV-18 pos 48 43
HPV-16 pos 31 28
HPV pos, other types 7 6
HPV neg 25 23
Total 111
Table 3 p53, codon 72, genotypic distribution in normal controls and HPV
positive and negative cervical adenocarcinomas
Pro/Pro (%) Pro/Arg (%) Arg/Arg (%) Total
Normal controls 16 (9) 83 (44) 89 (47) 188
Adenocarcinomas
HPV-18 pos 0 (0) 15 (31) 33 (69) 48
HPV-16 pos 0 (0) 7 (23) 24 (77) 31
HPV-X pos 0 (0) 2 (29) 5 (71) 7
HPV neg 0 8 (32) 17 (68) 25
Total 0 32 (29) 79 (71) 111of infection and the malignant properties of the virus in Swedish
women (Zehbe et al, 1998; Andersson et al, 2000). 
Apparently, the interplay between the human genotype and
oncogenic variants of HPV are of importance for the risk of the
development of cervical cancer. However, the evaluation of this
interplay is complicated by the normal variation of the human
genoma in different geographic regions and by an uneven distribu-
tion of the types and variants of HPV in the world (Koutsky,
1997). The introduction of gynaecological screening, about 30
years ago, has been successful in reducing the rate of incidence of
squamous carcinoma of the cervix in the developed countries
(Möhlck et al, 1994; Bergström et al, 1999). However, during the
same time period, the rate of incidence of adenocarcinoma of the
cervix has increased, especially in younger women (Miller et al,
1993). Evidently, cytological screening has not been able to reduce
the incidence of adenocarcinoma. The introduction of HPV
testing, an increased knowledge of the importance of polymor-
phism in the human genoma for the development of tumours and
continued research on the oncogenic properties of the different
types and variants of HPV are considered as instrumental in
reducing the incidence of cervical adenocarcinoma. 
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